MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.07
-12.46
-24.66%
Pre Market: 38.00 -0.07 -0.18% 04:44 03/03 EST
OPEN
38.00
PREV CLOSE
50.53
HIGH
39.42
LOW
33.84
VOLUME
133
TURNOVER
--
52 WEEK HIGH
57.21
52 WEEK LOW
22.65
MARKET CAP
3.46B
P/E (TTM)
-14.5183
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Crude Oil Down 1.5%; Communication Systems Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.08% to 31,562.10 while the NASDAQ fell 0.87% to 13,470.33. The S&P also fell, dropping 0.14% to 3,896.45.
Benzinga · 13h ago
DDD, NVAX, LMND and RKT among midday movers
Gainers: NanoViricides, Inc. (NNVC) +89%.Communications Systems, Inc. (JCS) +74%.Amyris, Inc. (AMRS) +41%.Hovnanian Enterprises, Inc. (HOV) +37%.Rocket Companies, Inc. (RKT) +36%.Perion Network Ltd. (PERI) +27%.The OLB Group, Inc. (OLB) +25%.Novan, Inc.
Seekingalpha · 15h ago
Mid-Day Market Update: Nasdaq Down 100 Points; NanoViricides Shares Spike Higher
Midway through trading Tuesday, the Dow traded down 0.18% to 31,478.24 while the NASDAQ fell 0.77% to 13,483.57. The S&P also fell, dropping 0.40% to 3,886.37.
Benzinga · 16h ago
FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another Delay
FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.
Investor's Business Daily · 17h ago
NanoViricides, CHF Solutions leads healthcare gainers; FibroGen, Neuronetics among major losers
Gainers: NanoViricides NNVC +63%, CHF Solutions CHFS +25%, Avenue Therapeutics (ATXI) +19%, Fortress Biotech FBIO +17%, STRATA Skin Sciences (SSKN) +15%.Losers: FibroGen FGEN -30%, Neuronetics STIM -14%, RedHill Biopharma RDHL -13%, Morphic Holding (MORF) ...
Seekingalpha · 17h ago
DJ FibroGen Down Nearly 31%, On Pace for Record Percent Decrease -- Data Talk
Dow Jones · 18h ago
Mid-Morning Market Update: Markets Mostly Lower; Target Profit Tops Views
Following the market opening Tuesday, the Dow traded up 0.04% to 31,549.29 while the NASDAQ fell 0.52% to 13,518.42. The S&P also fell, dropping 0.20% to 3,894.08.
Benzinga · 18h ago
FibroGen shares plummet 24% as FDA meeting, Jefferies downgrade weigh
Jefferies analyst Michael Yee has downgraded shares of FibroGen, Inc. (FGEN) to hold from buy.He also lower his price target to $45 from $75.Yee says that yesterday's announcement that the
Seekingalpha · 19h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FGEN. Analyze the recent business situations of FibroGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FGEN stock price target is 62.33 with a high estimate of 91.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 343
Institutional Holdings: 75.54M
% Owned: 83.00%
Shares Outstanding: 91.01M
TypeInstitutionsShares
Increased
71
5.70M
New
50
500.65K
Decreased
73
3.12M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Director
James Schoeneck
Chief Executive Officer/Director
Enrique Conterno
Chief Financial Officer
Pat Cotroneo
Other
K. Peony Yu
Senior Vice President
Christine Chung
Senior Vice President
Elias Kouchakji
Other
Percy Carter
Other
Mark Eisner
Other
Thane Wettig
Lead Director/Independent Director
Thomas Kearns
Director
Aoife Brennan
Director
Benjamin Cravatt
Independent Director
Suzanne Blaug
Independent Director
Jeffrey Edwards
Independent Director
Jeffrey Henderson
Independent Director
Maykin Ho
Independent Director
Kalevi Kurkijarvi
Independent Director
Gerald Lema
Independent Director
Rory Riggs
Independent Director
Toshinari Tamura
  • Dividends
  • Splits
  • Insider Activity
No Data
About FGEN
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.